Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2 results

Filters applied: . Clear all
Page 1
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0).
Chabrun F, Schwartz D, Gentile S, Mai E, Gupta T, Perry J, Santos DCD, Hielscher T, Werly A, Schmidt S, Theodorakakou F, Fotiou D, Liacos C, Kanellias N, Gisbert N, Martin-Sanchez E, Termini R, Waldschmidt J, Chavda S, Ainley L, Vià MCD, de Magistris C, Pettine L, Timonian M, Alberge JB, Patel V, Costello P, Tobia C, Phan S, Lamb J, Silverio MT, Davis M, O'Donnell E, Marinac C, Nadeem O, Bolli N, Yong K, Kortüm M, Einsele H, Manteca MVM, Kumar S, Miguel JS, Paiva B, Kastritis E, Dimopoulos M, Raab M, Trippa L, Ghobrial I. Chabrun F, et al. Among authors: manteca mvm. Res Sq [Preprint]. 2025 Jun 3:rs.3.rs-6696313. doi: 10.21203/rs.3.rs-6696313/v1. Res Sq. 2025. PMID: 40502745 Free PMC article. Preprint.
Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.
Dimopoulos MA, Beksac M, Pour L, Delimpasi S, Vorobyev V, Quach H, Spicka I, Radocha J, Robak P, Kim K, Cavo M, Suzuki K, Wilkes J, McNamara S, Phillips-Jones A, Morris K, Pompilus F, Purser M, Sule N, Kremer B, Loubert A, Bunod L, M'Hari M, Zhou XL, Fulci G, Mateos MV, Trudel S; DREAMM-8 investigators. Dimopoulos MA, et al. Lancet Haematol. 2025 Nov;12(11):e876-e886. doi: 10.1016/S2352-3026(25)00256-X. Lancet Haematol. 2025. PMID: 41193117 Clinical Trial.